Clinical Development of Immunotherapy in Urothelial Cancer

Speaker
  • Assistant Research Physician, National Institutes of Health, National Cancer Institute, Genitourinary Malignancy Branch and the Laboratory of Tumor Immunology and Biology
    BIOGRAPHY

Abstract

Platinum-based chemotherapy has been the cornerstone for treating metastatic urothelial cancer, which compromises the majority of bladder cancer. While urothelial cancer is chemosensitive, patients often do not have a durable response and ultimately progress. Until recently patients were left with less effective second line chemotherapy options, but this has changed with the advent of immunotherapy. The United States Food and Drug Administration approved two programmed death-1 (PD-1) inhibitors and three programmed death ligand-1 (PD-L1) in 2016-2017 for the second line setting. Adding check point inhibitors to our armamentarium has been revolutionary, however there are opportunities to improve with strategies to increase response rates and apply immunotherapy to earlier disease stages.

Learning Objectives:

1. Understand the current role of checkpoint inhibitors in metastatic urothelial cancer

2. Identify areas where immunotherapy could impact urothelial cancer treatment


Show Resources
You May Also Like
JUN 28, 2022 7:00 AM PDT
JUN 28, 2022 7:00 AM PDT
Date: June 28, 2022 Time: 3:00pm (BST), 4:00pm (CET), 9:00am (CST), 7am (PST) Light-sheet microscopy is an extremely versatile imaging technique with a vast range of implementations that are...
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
MAR 16, 2022 8:00 AM PDT
C.E. CREDITS
MAR 16, 2022 8:00 AM PDT
Date: March 16, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CET) Handling of potent and/or hazardous substances is commonplace in sev.....
JUN 21, 2022 6:00 AM PDT
JUN 21, 2022 6:00 AM PDT
Date: June 21, 2022 Time: 6:00am (PDT), 9:00am (EDT), 3:00pm (CEST) The global understanding and practice of medicine is currently undergoing a revolutionary change. This shift to precision...
APR 28, 2022 8:00 AM PDT
APR 28, 2022 8:00 AM PDT
Date: April 28, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Human pluripotent stem cells (PSCs) and their derivatives hold great potentials in...
APR 26, 2022 7:00 AM PDT
C.E. CREDITS
APR 26, 2022 7:00 AM PDT
Date: April 19, 2022 Time: 7:00am (PDT), 10:00am (EDT), 4:00pm (CEST) High-content (HC) phenotypic profiling approaches are a powerful tool to study the effect of biological, genetic, and ch...
Loading Comments...
Show Resources
Attendees